Whether HIV patients had hepatitis or not didn't change the benefit of visceral fat loss on liver enzymes when taking tesamorelin.

Scientific Claim

Viral hepatitis status did not significantly modify the association between visceral adipose tissue reduction and improvements in liver enzymes among tesamorelin-treated HIV-infected patients.

Original Statement

“The relationship between responder status and change in ALT or AST among tesamorelin-treated patients was not modified by viral hepatitis status.”

From study:Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The study design supports association claims. The language correctly describes the lack of modification without implying causation.

Evidence from Studies

Supporting (1)

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Randomized Controlled Trial

Human

2017 Oct 23

Contradicting (0)

No contradicting evidence found

Source Study

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Score: 62

DOI: 10.1097/QAD.0000000000001614

Similar Assertions

Whether people with HIV had hepatitis or not didn't change the relationship between losing belly fat and improving liver enzymes.

92%

Whether HIV patients had hepatitis or not didn't change the link between losing visceral fat and improving liver enzyme levels.

87%

When belly fat decreases in people with HIV, liver fat also tends to decrease, showing a connection between these two types of fat.

85%

For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from tesamorelin treatment had much bigger drops in their liver enzyme levels compared to those who didn't lose much fat.

85%

HIV patients with high liver enzymes who lost enough belly fat from tesamorelin were more than twice as likely to have their ALT levels return to normal compared to those who didn't lose much fat.

83%